Calcium channel blockers - benefits upon vascular biology in hypertensive patients

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 13, Issue 1, 2015, Pages 54-62

  Duda Seiman, Daniel ^a   Duda Seiman, Corina ^b   Borcan, Florin ^a   Borcan, Livia Cristina ^c   Mancas, Silvia ^a   Avram, Speranta ^d  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b WEST UNIVERSITY OF TIMISOARA   (Romania)

^c Department of Dermatology   (Romania)

^d UNIVERSITY OF BUCHAREST   (Romania)

Author keywords

Cilnidipine; Conduit artery function evaluation; Dihydropyridine; In silico; Lercanidipine; Molecular descriptors

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CILNIDIPINE; LERCANIDIPINE; LOW DENSITY LIPOPROTEIN; ANTIHYPERTENSIVE AGENT; DIHYDROPYRIDINE DERIVATIVE;

ADULT; ANTHROPOMETRY; ARTERIAL STIFFNESS; ARTICLE; ATHEROGENESIS; BLOOD PRESSURE MONITORING; BODY MASS; CARDIOVASCULAR RISK; COMPUTER MODEL; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; HYPERTENSION; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MIDDLE AGED; MOLECULAR MODEL; PULSE WAVE; SYSTOLIC BLOOD PRESSURE; VASCULAR BIOLOGY; AGED; BLOOD PRESSURE; CHEMISTRY; DRUG EFFECTS; PATHOPHYSIOLOGY;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PULSE WAVE ANALYSIS; VASCULAR STIFFNESS;

EID: 84939794628     PISSN: 18715257     EISSN: 18756182     Source Type: Journal    
DOI: 10.2174/187152571301150730115442     Document Type: Article

References (36)

1. Aouam, K.; Berdeaux, A. Dihydropyridines from the first to the fourth generation: better effects and safety. Therapie, 2003, 58(4), 333-339.
2. Borghi, C. Lercanidipine in hypertension. Vasc. Health Risk Manag., 2005, 1(3), 173-182.
3. Messerli, F.H. Calcium antagonists in hypertension: From hemodynamics to outcomes. Am. J. Hypertens., 2002, 15(7Pt2), 94S-97S.
4. Li, Y.; Cao, Z. In: Clinical toxicology. Principles and mechanisms; Barile, Ed.; CRC Press LLC: Boca Raton, 2004; pp. 207-222.
5. Kondo, T.; Goto, R.; Sonoda, K.; Yasuda, T.; Ono, K.; Takaki, Y.; Yatsuda, R.; Miyamura, N.; Araki, E. Plasma rennin activity and aldosterone concentration are not altered by the novel calcium channel antagonist, azelnidipine, in hypertensive patients. Inter Med, 2010, 49(7), 637-643.
6. Nakamura, E.; Akashi, H.; Hiromatsu, S.; Tanaka, A.; Onitsuka, S.; Aoyagi, S. Azelnidipine dicreases plasma matrix metalloproteinase-9 levels after endovascular abdominal aortic aneurysm repair. Kurume Med. J., 2009, 56(1 2), 25-32.
7. Mancia, G.; De Backer, G.; Dominiczak, A.; Cifkova, R.; Fagard, R.; Germano, G.; Grassi, G.; Heagerty, A.M.; Kjeldsen, S.E.; Laurent, S.; Narkiewicz, K.; Ruilope, L.; Rynkiewicz, A.; Schmieder, R.E.; Struijker Boudier, H.A.; Zanchetti, A.; Vahanian, A.; Camm, J.; De Caterina, R.; Dean, V.; Dickstein, K.; Filippatos, G.; Funck-Brentano, C.; Hellemans, I.; Kristensen, S.D.; McGregor, K.; Sechtem, U.; Silber, S.; Tendera, M.; Widimsky, P.; Zamorano, J.L.; Kjeldsen, S.E.; Erdine, S.; Narkiewicz, K.; Kiowski, W.; Agabiti-Rosei, E.; Ambrosioni, E.; Cifkova, R.; Dominiczak, A.; Fagard, R.; Heagerty, A.M.; Laurent, S.; Lindholm, L.H.; Mancia, G.; Manolis, A.; Nilsson, P.M.; Redon, J.; Schmieder, R.E.; Struijker-Boudier, H.A.; Viigimaa, M.; Filippatos, G.; Adamopoulos, S.; Agabiti-Rosei, E.; Ambrosioni, E.; Bertomeu, V.; Clement, D.; Erdine, S.; Farsang, C.; Gaita, D.; Kiowski, W.; Lip, G.; Mallion, J.M.; Manolis, A.J.; Nilsson, P.M.; O'Brien, E.; Ponikowski, P.; Redon, J.; Ruschitzka, F.; Tamargo, J.; van Zwieten, P.; Viigimaa, M.; Waeber, B.; Williams, B.; Zamorano, J.L.; The task force for the management of arterial hypertension of the European Society of Hypertension, The task force for the management of arterial hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens., 2007, 25(6), 1105-1187.
8. Burnier, M.; Pruijm, M.; Wuerzner, G. Treatment of essential hypertension with calcium channel blockers: What is the place of lercanidipine? Expert Opin. Drug Metab. Toxicol., 2009, 5(8), 981-987.
9. Romito, R.; Pansini, M.I.; Perticone, F.; Antonelli, G.; Pitzalis, M.; Rizzon, P. Comparative effect of lercanidipine, felodipine, and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: The Lercanidipine in Adults (LEAD) Study. J. Clin. Hypertens., 2003, 5(4), 249-253.
10. Cesarone, M.R.; Incandela, L.; Ledda, A.; De Sanctis, M.T.; Steigerwalt, R.; Pellegrini, L.; Bucci, M.; Belcaro, G.; Ciccarelli, R. Pressure and microcirculatory effects of treatment with lercanidipine in hypertensive patients and in vascular patients with hypertension. Angiology, 2000, 51(8Pt2), S53-S63.
11. Ram, C.V. Hypertension, possible vascular protection and lercanidipine. Expert Rev. Cardiovasc. Ther., 2006, 4(6), 783-788.
12. Makaraounas-Kirchmann, K.; Glover-Koudounas, S.; Ferrari, P. Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers. Clin. Ther., 2009, 31(8), 1652-1663.
13. Avram, S.; Buiu, C.; Duda-Seiman, C.; Borcan, F.; Duda-Seiman, D.; Mihailescu, D. In: Recent Trends on QSAR in the Pharmaceutical Perceptions; Khan, Ed.; Bentham Science Publishers: Bussum, 2012, pp. 63-98.
14. Duda-Seiman, C.; Avram, S.; Duda-Seiman, D.; Bumbacila, B.; Borcan, F., Cinca, R. In: Recent Trends on QSAR in the Pharmaceutical Perceptions; Khan, Ed.; Bentham Science Publishers: Bussum, 2012, pp. 51-62.
15. Kostis, J.B. Commentary. A new approach to primary prevention of cardiovascular disease. Am. J. Med., 2007, 120(9), 746-747.
16. Napoli, C.; Lerman, L.O.; De Nigris, F.; Gossl, M.; Balestrieri, M.L.; Lerman, A. Rethinking primary prevention of atherosclerosisrelated diseases. Circulation, 2006, 114(23), 2517-2527.
17. Bos, W.J.; Verrij, E.; Vincent, H.H.; Westerhof, B.E.; Parati, G.; van Montfrans, G.A. How to assess mean blood pressure properly at the brachial artery level. J. Hypertens., 2007, 25(4), 751-755.
18. Graham, I.; Atar, D.; Borch-Johnsen, K.; Boysen, G.; Burell, G.; Cifkova, R.; Dallongeville, J.; De Backer, G.; Ebrahim, S.; Gjelsvik, B.; Herrmann-Lingen, C.; Hoes, A.; Humphries, S.; Knapton, M.; Perk, J.; Priori, S.G.; Pyorala, K.; Reiner, Z.; Ruilope, L.; Sans-Menendez, S.; Op Reimer, W.S.; Weissberg, P.; Wood, D.; Yarnell, J.; Zamorano, J.L.; Walma, E.; Fitzgerald, T.; Cooney, M.T.; Dudina, A.; Vahanian, A.; Camm, J.; De Caterina, R.; Dean, V.; Dickstein, K.; Funck-Brentano, C.; Filippatos, G.; Hellemans, I.; Kristensen, S.D.; McGregor, K.; Sechtem, U.; Silber, S.; Tendera, M.; Widimsky, P.; Zamorano, J.L.; Altiner, A.; Bonora, E.; Durrington, P.N.; Fagard, R.; Giampaoli, S.; Hemingway, H.; Hakansson, J.; Kjeldsen, S.E.; Larsen, M.L.; Mancia, G.; Manolis, A.J.; Orth-Gomer, K.; Pedersen, T.; Rayner, M.; Ryden, L.; Sammut, M.; Schneiderman, N.; Stalenhoef, A.F.; Tokgözoglu, L.; Wiklund, O.; Zampelas, A.; European Society of Cardiology (ESC); European Association for Cardiovascular Prevention and Rehabilitation (EACPR); Council on Cardiovascular Nursing; European Association for Study of Diabetes (EASD); International Diabetes Federation Europe (IDFEurope); European Stroke Initiative (EUSI); Society of Behavioural Medicine (ISBM); European Society of Hypertension (ESH); WONCA Europe (European Society of General Practice/Family Medicine); European Heart Network (EHN); European Atherosclerosis Society (EAS). European guidelines on cardiovascular disease prevention in clinical practice: Full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur. J. Cardiovasc. Prev. Rehabil., 2007, 14(S2), S1-S113.
19. Friedewald, W.T.; Levy, R.I.; Fredrickson, D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem., 1972, 18(6), 499-502.
20. Emerging Risk Factors Collaboration; Di Angelantonio E.; Sarwar, N.; Perry, P.; Kaptoge, S.; Ray, K.K.; Thompson, A.; Wood, A.M.; Lewington, S.; Sattar, N.; Packard, C.J.; Collins, R.; Thompson, S.G.; Danesh, J. Major lipids, apolipoproteins, and risk of vascular disease. JAMA, 2009, 302(18), 1993-2000.
21. Yamamoto, T.; Niwa, S.; Ohno, S.; Tokumasu, M.; Masuzawa, Y.; Nakanishi, C.; Nakajo, A.; Onishi, T.; Koganei, H.; Fujita, S.; Takeda, T.; Kito, M.; Ono, Y.; Saitou, Y.; Takahara, A.; Iwata, S.; Shoji, M. The structure-activity relationship study on 2-, 5-, and 6- position of the water soluble 1,4-dihydropyridine derivatives blocking N-type calcium channels. Bioorg. Med. Chem. Lett., 2008, 18(17), 4813-4816.
22. Yamamoto, T.; Niwa, S.; Ohno, S.; Onishi, T.; Matsueda, H.; Koganei, H.; Uneyama, H.; Fujita, S.; Takeda, T.; Kito, M.; Ono, Y.; Saitou, Y.; Takahara, A.; Iwata, S.; Shoji, M. Structure-activity relationship study of 1,4-dihydropyridine derivatives blocking Ntype calcium channels. Bioorg. Med. Chem. Lett., 2006, 16(4), 798-802.
23. Starčević, J.N.; Petrovič, D. Carotid intima media-thickness and genes involved in lipid metabolism in diabetic patients using statins - a pathway toward personalized medicine. Cardiovasc. Hematol. Agents Med. Chem., 2013, 11(1), 3-8.
24. Laurent, S.; Boutouyrie, P.; Asmar, R.; Gautier, I.; Laloux, B.; Guize, L.; Ducimetiere, P.; Benetos, A. Aortic stiffness is an independent predictor of all cause and cardiovascular mortality in hypertensive patients. Hypertension, 2001, 37(5), 1236-1241.
25. Laurent, S.; Katsahian, S.; Fassot, C.; Tropeano, A.I.; Gautier, I.; Laloux, B.; Boutouyrie, P. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke, 2003, 34(5), 1203-1206.
26. Shoji, T.; Emoto, M.; Shinohara, K.; Kakiya, R.; Tsujimoto, Y.; Kishimoto, H.; Ishimura, E.; Tabata, T.; Nishizawa, Y. Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J. Am. Soc. Nephrol., 2001, 12(10), 2117-2124.
27. Koivistoinen, T.; Hutri-Kähönen, N.; Juonala, M.; Kööbi, T.; Aatola, H.; Lehtimäki, T.; Viikari, J.S.; Raitakari, O.T.; Kähönen, M. Apolipoprotein B is related to arterial pulse wave velocity in young adults: The Cardiovascular Risk in Young Finns Study. Atherosclerosis, 2011, 214(1), 220-224.
28. Nakamura, M.; Sato, K.; Nagano, M. Estimation of aortic systolic blood pressure in community-based screening: The relationship between clinical characteristics and peripheral to central blood pressure differencies. J. Hum. Hypertens., 2005, 19(3), 251-253.
29. Lautsch, D.; Saely, C.H.; Traindl, O.; Eber, B.; Pfeiffer, K.P.; Drexel, H. Is there a link between non-HDL-cholesterol and blood pressure? An age and gender directed analysis of 7500 hypertensive outpatients. J. Kardiol - Austrian J. Cardiol., 2012, 19(1-2), 11-16.
30. Williams, B.; Lacy, P.S.; Thom, S.M.; Cruickshank, K.; Stanton, A.; Collier, D.; Hughes, A.D.; Thurston, H.; O'Rourke, M.; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential Impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) Study. Circulation, 2006, 113(9), 1213-1225.
31. Cavalcante, J.L.; Lima, J.A.C.; Redheuil, A.; Al-Mallah, M.H. Aortic stiffness. Current understanding and future directions. J. Am. Coll. Cardiol., 2011, 57(14), 1511-1522.
32. Ghiadoni, L.; Bruno, R.M.; Stea, F.; Virdis, A.; Taddei, S. Central blood pressure, arterial stiffness, and wave reflection: New targets of treatment in essential hypertension. Curr. Hypertens. Rep., 2009, 11(3), 190-196.
33. Deary, A.J.; Schumann, A.L.; Murfet, H.; Haydock, S.; Foo, R.S.; Brown, M.J. Influence of drugs and gender on the arterial pulse wave and natriuretic peptide secretion in untreated patients with essential hypertension. Clin. Sci. (Lond), 2002, 103(5), 493-499.
34. Morgan, T.; Lauri, J.; Bertram, D.; Anderson, A. Effect of different antihypertensive drug classes on central aortic pressure. Am. J. Hypertens., 2004, 17(2), 118-123.
35. London, G.M.; Pannier, B.; Guerin, A.P.; Marchais, S.J.; Safar, M.E.; Cuche, J.L. Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation, 1994, 90(6), 2786-2796.
36. Mackenzie, I.S.; McEniery, C.M.; Dhakam, Z.; Brown, M.J.; Cockcroft, J.R.; Wilkinson, I.B. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension, 2009, 54(2), 409-413